📰 Johan Dighed News
Page 5 - Johan Dighed News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Johan Dighed. Real-time updates on events, politics, business and more.
December 1, 2021
Investegate announcements from Karolinska Development AB (pub, Karolinska Development’s portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin
December 1, 2021
STOCKHOLM SWEDEN - December 1, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of
November 3, 2021
STOCKHOLM, SWEDEN - November 3, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Umecrine Cognition will present new scientific results showing that the
October 27, 2021
STOCKHOLM, SWEDEN - October 27, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Dilafor, a drug development company focusing on the development of tafoxiparin
October 19, 2021
STOCKHOLM, SWEDEN - October 19, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Umecrine Cognition has entered a collaboration with Professor Trevor
October 4, 2021
Investegate announcements from Karolinska Development AB (pub, Karolinska Developments portfolio company OssDsign receives expanded FDA market clearance for OssDsign Cranial PSI
August 12, 2021
Investegate announcements from Karolinska Development AB (pub, Karolinska Developments portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program
August 12, 2021
STOCKHOLM, SWEDEN - August 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics
June 10, 2021
June 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has completed a successful and fully subscribed unit offering bringing the company SEK 50 million and that Biosergen’s share will be listed on Nasdaq First North Growth Market in Stockholm on June 24, 2021. The proceeds from the offering allow Biosergen to launch clinical trials of its antifungal drug candidate BSG005 with the ambition of filing for market approval in th...
June 10, 2021
STOCKHOLM, SWEDEN - June 10, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has completed a successful and fully subscribed unit offering